Resource Library

This resource library includes tools and resources such as reports, white papers, news, patient information and downloadable materials related to the biosimilars, specific to multiple sclerosis (MS) and select anti-inflammatory/rheumatological biosimilars. Additionally, it includes key documents needed for your practice such as Medication Use Evaluation (MUE), P&T Committee articles, and checklists to help onboard new and emerging biosimilar products. Simply by clicking on the areas you wish to explore and access these valuable tools and resources.

106 Results

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

Topics: Rheumatology

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Topics: Rheumatology

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

Topics: Rheumatology

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Topics: Rheumatology

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative p

Topics: Rheumatology

BIosimilar Report 2023 (Cardinal)

Topics: Economics

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects

Topics: Rheumatology

A review of biosimilars for rheumatoid arthritis

Topics: Rheumatology

Biosimilars (FDA resource)

Topics: Legal / Regulatory

A health economic guide to market access of biosimilars

Topics: Economics

Biosimilars at 10 Years

Topics: Economics

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis

Topics: Economics

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative

Topics: Implementation, Payers

Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center

Topics: P&T Committee

Factors influencing the economics of biosimilars in the US

Topics: Economics

NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

Topics: Oncology

Barriers to Oncology Biosimilars Update in the United States (The Oncologist)

Topics: Oncology

Rationale, Opportunities, and Reality of Biosimilar Medications

Topics: Economics

Biosimilar Interchangeability Laws

Topics: Legal / Regulatory

Best Practices in Formulary Management Unique Strategies for Biosimilar Adoption

Topics: Implementation

Page 4 of 6

← Previous Next →

Resource Library

Resource type

Topic

Search for keywords in resource title

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative p

BIosimilar Report 2023 (Cardinal)

Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects

A review of biosimilars for rheumatoid arthritis

Biosimilars (FDA resource)

A health economic guide to market access of biosimilars

Biosimilars at 10 Years

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis

Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative

Navigating uncharted waters: Developing a standardized approach for evaluating and implementing biosimilar products at a comprehensive cancer center

Factors influencing the economics of biosimilars in the US

NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives

Barriers to Oncology Biosimilars Update in the United States (The Oncologist)

Rationale, Opportunities, and Reality of Biosimilar Medications

Biosimilar Interchangeability Laws

Best Practices in Formulary Management Unique Strategies for Biosimilar Adoption